A potential acquisition opportunity has emerged for Science in Sport, a prominent player in the UK sports nutrition sector. The company recently announced that BD-Capital, a private equity firm, has shown interest in purchasing Science in Sport at an estimated price of £0.34 per share. While the discussions are still in their early stages, BD-Capital's proposal has sparked significant attention within the industry. Notably, Science in Sport markets its products under well-known brands such as SiS and PhD Nutrition, making it an attractive target for investment firms.
Science in Sport’s board has established an independent committee to thoroughly assess the tentative offer. If BD-Capital confirms its intention to proceed with a formal bid by the deadline on 14 May, the committee will evaluate whether to recommend the deal. BD-Capital, which already holds stakes in other health-related companies like Bonusan and Symprove, could expand its portfolio significantly through this acquisition. Meanwhile, Science in Sport is focusing on improving its financial performance after reporting a decline in revenue for the first half of 2024, despite showing signs of operational improvement.
The future appears promising for Science in Sport as the company anticipates a return to growth in the coming year. Despite experiencing a revenue drop in 2024, the business expects its adjusted EBITDA to more than double, reflecting ongoing improvements in efficiency and cost management. Moving forward, the organization remains optimistic about sustaining this upward trend into 2025. This scenario underscores the importance of strategic planning and adaptability in maintaining long-term success in competitive industries. Companies that can effectively navigate challenges while seizing opportunities often emerge stronger, proving that resilience and innovation are key ingredients for prosperity.